top of page

Nammi Therapeutics Awarded Grant by California Institute for Regenerative Medicine (CIRM)

Writer's picture: Nammi TherapeuticsNammi Therapeutics

Updated: Feb 9, 2023

The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the development of a safer, more tolerable alternative.


The CIRM Board awarded $3,999,113 to Dr. David Stover and Nammi Therapeutics to complete the manufacture and testing needed to gain FDA permission for a clinical trial for multiple myeloma and advanced solid tumors. The therapy QXL 138AM, a “masked immunocytokine,” binds to and kills the tumor by activating the immune system.


237 views0 comments

Recent Posts

See All

Opmerkingen


©2019 Nammi Therapeutics, Inc.

bottom of page